Objective-Because population-based data are lacking, we assessed the cross-sectional association between serum testosterone levels and endothelial function, as measured by flow-mediated dilation (FMD) and nitroglycerin-mediated dilation (NMD) of the brachial artery, in men from the population-based Study of Health in Pomerania. Methods and Results-Personal characteristics, including major cardiovascular confounders, were collected in 722 men, aged 25 to 85 years. Serum total testosterone and sexual hormone-binding globulin (SHBG) levels were determined by chemiluminescence immunoassays. Free testosterone levels were calculated according to the law of mass action. FMD and NMD measurements were performed using standardized ultrasound techniques. FMD and NMD values below the 20th percentile were considered decreased. Multivariable logistic regression analyses revealed an association for each decrement of total testosterone standard deviation (6.0 nmol/L) with decreased FMD after adjustment for potential confounders (odds ratio 1.30, 95% confidence interval 1.04 -1.63; Pϭ0.023). Multiple adjusted findings for free testosterone were similar (odds ratio 1.37, 95% confidence interval 1.06 -1.76; Pϭ0.016). There was no such association of SHBG levels with decreased FMD. Neither testosterone nor SHBG levels were significantly associated with decreased NMD. Conclusion-Lower serum total and free testosterone levels are associated with impaired endothelial function in this population-based sample of men. (Arterioscler Thromb Vasc Biol. 2012;32:481-486.)
T here is increasing evidence that low serum testosterone levels are associated with increased cardiovascular mortality in men. [1] [2] [3] In previous cross-sectional studies, low testosterone levels were associated with cardiovascular risk factors, to include abdominal obesity 4 and hypertension. 5 Furthermore, low serum total testosterone levels are a strong predictor for incident metabolic syndrome. 6 However, the exact pathophysiological mechanisms that link low total testosterone levels to increased cardiovascular mortality have not yet been identified. 7 Impaired flow-mediated dilation (FMD) represents endothelial dysfunction and precedes the development of clinically apparent atherosclerosis in subjects with cardiovascular risk factors such as diabetes mellitus, arterial hypertension, hypercholesterolemia, and smoking. 8 Low FMD values predict cardiovascular events independently of established atherosclerosis. 9 In contrast to FMD, nitroglycerin-mediated dilation (NMD) is considered to represent endotheliumindependent vasodilation. 10 Current knowledge concerning the impact of testosterone on endothelial function in men is primarily derived from small studies in individuals during exogenous testosterone administration. [11] [12] [13] [14] [15] Testosterone administration consistently led to FMD reduction in hypogonadal men 11, 14, 15 and bodybuilders taking anabolic steroids. 12, 13 Until now, only 1 study, in 187 Japanese outpatients, has investigated the relationship between testosterone levels and FMD without exogenous testosterone administration. 16 In these outpatients with high cardiovascular risk profiles, there was an association of low testosterone levels with decreased FMD independent of major cardiovascular confounders.
Because of the known associations of low testosterone levels with cardiovascular mortality, on the one hand, and of low FMD values with cardiovascular mortality on the other, we hypothesized that low testosterone levels may be associated with impaired endothelial function as measured by FMD. Because of the lack of population-based data, we aimed to analyze the association of total and calculated free testosterone, as well as sexual hormone-binding globulin (SHBG) levels, with FMD and NMD in a large, population-based sample of 722 men from the Study of Health in Pomerania (SHIP).
Methods

Study Population
Details on the SHIP study design have been previously published. 17 In brief, SHIP is a population-based study conducted in the northeast area of Germany. The first follow-up examination (SHIP-1) was conducted 5 years (mean 5.2Ϯ0.5 years) after baseline and comprised 3300 subjects (1589 men, 83.5% of the initial eligible population). The study was approved by the ethics committee of the University of Greifswald. All participants gave written informed consent.
Of the 1589 male follow-up participants in SHIP-1, 875 (55.1%) volunteered for FMD measurements of the brachial artery between March 2003 and October 2006. Exclusion criteria for FMD measurements were equipment malfunction (nϭ20) and any medical contraindication (nϭ8), including hypotension with systolic blood pressure below 100 mm Hg (nϭ5). Image quality of 86 FMD examinations was insufficient for correct readings. Among the remaining 761 men with sufficient FMD image quality, 23 men who used opiates (anatomic-therapeutical-chemical [ATC] codes N02AA, A07DA02, R05DA, R05FA0, nϭ3), glucocorticoids (ATC codes R03BA, nϭ9; H02AB, nϭ8), testosterone 5␣ reductase inhibitors (ATC code G04CB, nϭ2) or sexual hormone antagonists (ATC code L02B, nϭ1) were also excluded from analysis. None of the subjects reported taking sexual hormones (ATC code G03) or anabolic steroids (ATC code A14A). An additional 16 men with no blood drawn or no values for total testosterone or SHBG were also not considered, which yielded a final study population of 722 men with both complete examinations of FMD of sufficient quality and measurements of total testosterone and SHBG.
Measurements
Information on sociodemographic characteristics, health behavior, medication intake, and previous medical history was collected by computer-assisted personal interviews. In the present study, we included age, smoking status (never, ex-smoker, current smoker), self-reported use of antihypertensive medication, and physician's diagnosis of liver and renal diseases. Diabetes mellitus was defined by self-reported physician's diagnosis or use of antidiabetic medication (ATC A10).
Waist circumference (WC) was measured to the nearest 0.1 cm using an inelastic tape midway between the lower rib margin and the iliac crest in the horizontal plane, with the subject standing comfortably with weight distributed evenly on both feet. Body mass index was calculated as weight in kilograms divided by the square of height in meters. After a 5-minute rest period, systolic and diastolic blood pressure were measured 3 times at the right arm of seated subjects using a digital blood pressure monitor (HEM-705CP, Omron Corporation, Tokyo, Japan), with each reading being followed by another rest period of 3 minutes. The mean of the second and third measurements was calculated and used for the present analyses. Systolic and diastolic blood pressures of Ն140 and Ն90 mm Hg, respectively, were considered increased. Hypertension was defined as increased systolic or diastolic blood pressure or use of antihypertensive medication.
Assays
Nonfasting blood samples were drawn from the cubital vein in the supine position. The samples were taken between 07:00 AM and 04:00 PM and analyzed immediately for all parameters except for testosterone and SHBG, for which serum was stored at Ϫ80°C. All assays were performed according to the manufacturer's recommendations by skilled technical personnel. Internal quality controls were performed at least daily. Serum creatinine levels were measured by a modified Jaffé method, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels were quantified by lipid electrophoresis as described previously. 4 High-sensitivity C-reactive protein was determined immunologically on a Behring Nephelometer II with commercially available reagents from Dade Behring (Eschborn, Germany). Renal disease was defined as a creatinine clearance below 50 mL/minute as estimated by the Cockcroft-Gault formula.
Levels of total testosterone and SHBG were measured from stored samples between April and May 2008 using a chemiluminescent immunometric assay on an Immulite 2500 analyzer (Siemens Immulite 2500, Siemens Healthcare Medical Diagnostics, Bad Nauheim, Germany) as previously described. 18 An aliquot of 2 levels of the manufacturer's control material, supplied with the reagent (SHBG Control, ref. LSHC1 and LSHC2, Siemens Healthcare Medical Diagnostics), was included within each SHBG series in single assay. During the course of the study, the interassay coefficient of variation was 4.5% with a systematic deviation of ϩ1.1% at the 4.7 nmol/L level and 7.2% with a systematic deviation of ϩ0.3% at 73 nmol/L level. For quality control of total testosterone measurements, an aliquot of 3 levels of the manufacturer's control material (Immunoassay Control, ref. CON6, lot 021, Siemens Healthcare Medical Diagnostics) was included within each series in single determination. During the course of the study, the interassay coefficient of variation was 14.3%, with a systematic deviation of Ϫ8.8% at the 4.1 nmol/L level, 10.5% with a systematic deviation of Ϫ4.4% at the 12.1 nmol/L level, and 13.6 with a systematic deviation of Ϫ8.5% at the 29.4 nmol/L level. Total testosterone and SHBG levels were used to calculate free testosterone levels as previously described [free testosterone levels (nmol/L)ϭ([Ϫaϩ͌b]/c)/10 Ϫ9 with aϭSHBG (nmol/L)Ϫtotal testosterone (nmol/L)ϩ23.43, bϭa 2 ϩ(4ϫ23.43ϫ total testosterone [nmol/L]) and cϭ2ϫ23.43ϫ10 9 for a standard average albumin concentration of 4.3 g/dL 19 ]. Total and free testosterone levels as wells as SHBG levels were divided by their negative SD to demonstrate the effect per value decrement.
Endothelial Function
FMD was assessed as described previously 20 between 07:00 AM and 04:00 PM. In brief, FMD of the brachial artery was assessed by measuring the increase of the brachial artery diameter during reactive hyperemia after transient forearm ischemia. The brachial artery was visualized using a 10 MHz linear array transducer (Cypress, Siemens, Erlangen, Germany). Ultrasonography was performed in a dark and quiet room. The participants lay quietly for 10 minutes before measurements. A blood-pressure cuff was placed around the right forearm 5 cm distally from the right antecubital crease. B-mode longitudinal images of the brachial artery were obtained at the level of the antecubital fossa. After marking the optimal position of the transducer, baseline images of the brachial artery were digitally stored. Arterial flow to the forearm was interrupted by insufflation of the forearm cuff for 5 minutes by 200 mm Hg or 50 mm Hg above systolic blood pressure, whichever was highest. Exactly 1 minute after cuff deflation, B-mode longitudinal images of the brachial artery were obtained for FMD measurements. After FMD measurements, volunteers lay quietly for 10 minutes to allow the diameters of the brachial arteries to return to baseline levels. NMD was measured 3 minutes after sublingual administration of nitroglycerin (400 g) in 636 male subjects (88.1%).
All measurements of brachial artery diameters were performed offline by independent sonographers and were subject to strict quality management. 20 Intrareader, intraobserver, interreader, and interobserver variability were evaluated in certification procedures. Before data collection, 25 images were measured twice by each participating reader, and 12 volunteers were examined twice by each participating observer. During data collection, observer certification procedures were repeated semiannually for 6 volunteers. At least 24 hours were required between 2 readings and examinations, respectively. All measurements of intrareader, intraobserver, interreader, and interobserver agreements with respect to FMD revealed a mean bias of Ͻ5% and ϩ2 SD bias of Ͻ25%. The applied quality measures and the results of certification procedures have been described elsewhere in detail. 20 End-diastolic vessel diameters were measured from the anterior to the posterior M-line (ie, the interface between the media and adventitia) of the vessel wall. Diameters were calculated from the average of 3 measurements of 4 consecutive cardiac cycles. Absolute FMD and NMD were calculated by subtracting baseline vessel diameters from postischemia and postnitroglycerin vessel diameters, respectively. Relative changes as expressed as percentage of absolute FMD and NMD to baseline diameters below the 20th percentile of each distribution (FMD Ͻ1.51%; NMD Ͻ7.55%) were considered decreased.
Statistical Analyses
Data on quantitative characteristics are provided as mean and SD. Data on qualitative characteristics are expressed as absolute numbers and percentage values. Comparisons between study population and nonparticipants were carried out using the Mann-Whitney U test (continuous data) and 2 test (nominal data). Multivariable logistic regression models were performed to calculate odds ratios (OR) for decreased FMD and NMD per SD decrement of total testosterone, free testosterone, and SHBG. The full model was adjusted for age, WC, smoking status, hypertension, diabetes mellitus, liver disease, renal disease, LDL and HDL cholesterol levels, and natural logtransformed C-reactive protein, as well as antihypertensive medication. Significant linearity of dose response relations was checked by applying multivariable fractional polynomial models. 21 Sensitivity analysis was conducted by adjustment for blood sampling time and time of FMD measurements. To control for possible selection bias introduced by exclusion of subjects, major variables of difference between study population and nonparticipants were used for inverse probability weighting in further sensitivity analyses. 22 A value of PϽ0.05 was considered statistically significant. All statistical analyses were performed using Stata 11 (Stata Corp, College Station, TX).
Results
The study population of 722 participating men was younger, had lower WC and C-reactive protein levels, and demonstrated lower proportions of diabetes mellitus and renal disease than did the male nonparticipants (nϭ867). Furthermore, the study population exhibited lower systolic and higher diastolic blood pressure-together with a lower proportion of hypertension and including less frequent use of antihypertensive medication-than did the nonparticipants. There was no difference in total testosterone levels between both groups. However, the study population had lower SHBG levels and therefore higher free testosterone levels than the nonparticipants. There were no differences between the 2 groups concerning smoking status, body mass index, liver disease, or HDL and LDL cholesterol levels ( Table 1 ). The study population had a mean baseline brachial artery diameter of 4.4 mm (SD: 0.5 mm) and a mean FMD of 4.3% (SD: 3.2%).
Multivariable logistic regression analyses revealed an association between each decrement of total testosterone SD of 6.0 nmol/L and decreased FMD with an age-adjusted OR of 1.24 (CI 1.01-1.53; Pϭ0.041). This relation was not substantially affected by adjustments for further potential confounders, including WC, smoking status, hypertension, diabetes mellitus, liver and renal disease, serum LDL and HDL cholesterol, and natural log-transformed C-reactive protein (OR 1.27, CI 1.01-1.59; Pϭ0.038) and antihypertensive medication (OR 1.30, CI 1.04 -1.63; Pϭ0.023). There were similar findings for the association of each decrement of free testosterone SD (0.13 nmol/L) with decreased FMD for the age-adjusted (OR 1.32, CI 1.04; 1.67; Pϭ0.023) and fully adjusted model (OR 1.37, CI 1.06 -1.76; Pϭ0.016). The use of 2 alternative calculations of free testosterone described by Sodergard et al 23 and Ly and Handelsman 24 did not substantially affect the major results. Fractional polynomial models confirmed these linear relations, because no other transformation of the independent variables improved the fit of the model. In contrast, there were no such associations with respect to SHBG in either the age-adjusted or fully adjusted model ( Table 2) .
Inverse probability weighting according to age, WC, and hypertension showed no overall impact on the results disclosed (data not shown). Furthermore, sensitivity analyses with additional adjustments for the time of day of blood sampling and the time of day of FMD examination did not substantially change the main results of the analyses: fully adjusted OR for total testosterone amounted to 1.30 (CI 1.04 -1.63; Pϭ0.024), and 1.36 (CI 1.06; 1.75; Pϭ0.017) for free testosterone. Bivariate associations of testosterone-related measurements with decreased NMD were positive for low free testosterone (OR 1.65, CI 1.29 -2.10; PϽ0.001) and inverse for low SHBG (OR 0.77, CI 0.64 -0.92; Pϭ0.004) in the unadjusted models. After adjustment for age and further confounders these findings did not persist. There was no association between low total testosterone and decreased NMD in either the unadjusted or adjusted models (Table 3 ).
Discussion
The present study is the first to report a cross-sectional association of low total and free testosterone levels with decreased endothelial function in a population-based sample of men over a broad age range.
Previous knowledge concerning the influence of testosterone levels on endothelial function in men was primarily derived from smaller studies in subjects either taking anabolic steroids [11] [12] [13] [14] [15] or in those with high cardiovascular risk. 16 Testosterone administration in patients with testosterone deficiency 11, 14, 15 or bodybuilders 12, 13 led to a reduction of FMD, which suggests an inhibitory effect of testosterone on endothelial function. In contrast, but in line with our results, another study in 187 Japanese outpatients demonstrated an association of low testosterone levels and decreased FMD independent of major cardiovascular confounders. 16 However, comparison of patient-based results with our population-based findings should be made with caution. Our data may give stronger support toward a relevant impact of testosterone on the cardiovascular system in male subjects under physiological conditions. It is not known whether the effect of testosterone on FMD is mediated by the association of testosterone with known or unknown cardiovascular risk factors or is mediated directly through effects on the vascular endothelium. Our data strongly suggest that the association of testosterone and FMD is independent of major classical cardiovascular risk factors. Further support for a direct effect of testosterone on endothelial function is derived from experimental studies. Acute administration of testosterone enhanced FMD in men with coronary heart disease 25 and increased vasodilation in coronary arteries of patients with coronary heart disease. 26 The presence of sex-hormone receptors in the cytosol and nuclear compartments of endothelial cells 27 makes a direct effect of testosterone on endothelial function plausible. Although our cross-sectional data are insufficient to establish biological causality, the present findings suggest that testosterone may play an important role in the regulation of vascular tone and reactivity. 28 Because of the observational character of SHIP, interventional measures, such as testosterone substitution, are not feasible. We are therefore unable to address the question of the beneficial cardiovascular effects of this treatment. However, several clinical studies suggested favorable effects of testosterone substitution, eg, on angina threshold in patients with coronary heart disease 29, 30 and on cardiovascular risk factors, such as insulin sensitivity, WC, and body composition. 31 On the other hand, unfavorable effects of testosterone substitution have also been reported. Testosterone substitution was associated with increased cardiovascular risk in older men with impaired mobility. 32 Also, the timing of testosterone substitution has remained an unsolved problem. Furthermore, the potentially increased risk of prostate cancer will remain a matter of debate until appropriately designed and powered trials have been conducted. Taken together, data from large clinical trials determining the risks and benefits of testosterone substitution are still lacking. 7 In contrast to FMD, NMD is a marker of endotheliumindependent vasodilation. 10 NMD was not independently associated with either total or free testosterone or SHBG levels in the present study, suggesting that testosterone levels may have an impact on vasoreactivity solely via the endothelium, given that forearm ischemia-induced FMD leads exclusively to shear stress mediated vasodilation via the nitric oxide system. 10 Several potential limitations of our study should be considered. The prevalence of known risk factors for atherosclerosis in our study population-eg, arterial hypertension (55%), smoking status (only 29% of the individuals were never smokers), and obesity (mean WC 98 cm)-is higher than in other population-based studies. 9 Furthermore, our study population differed from the whole male SHIP-1 population in a number of risk factors, such as age, WC, and hypertension. However, controlling for selection bias by inverse probability weighting did not substantially alter the present results of an association of lower testosterone levels with reduced FMD. Second, free testosterone levels were not measured directly but were calculated using standard equations. 19 Calculation of free testosterone levels by the method of Vermeulen reflects a generally accepted approach (e.g. 33 ). However, free testosterone levels can be calculated using various equations, potentially leading to different results. Calculation of free testosterone levels with alternative equations, as published by Sodergard et al 23 and Ly and Handelsman, 24 did not have a relevant impact on our major findings. Our analyses revealed almost identical associations for total and free testosterone levels with FMD and NMD, respectively. This lends support to the biological plausibility of this approach for calculating free testosterone levels. Third, measurements of total testosterone levels were based on a single serum sample. Single-point total testosterone measurement is known to reliably reflect the annual mean androgen level in middle-aged and elderly men. 34 Furthermore, sensitivity analyses, including adjustment for blood sampling time, showed no significant impact on the estimates. Fourth, testosterone is metabolized to numerous degradation products of biological activity. Currently, high-sensitivity tandem mass spectrometry is considered the most reliable for quantification of sexual hormone concentrations. 35 This laboratory platform was not available, and consequently neither estrogens, dihydrotestosterone, nor any other biologically active products of testosterone degradation have been measured in the SHIP-1 male population. As a result, it was not possible to investigate the potential association and interdependence of these metabolites with testosterone levels, on the one hand, and/or FMD on the other.
There are several strengths of our study: the large size of the population-based sample of men; comprehensive and detailed assessment of metabolic and cardiovascular confounding factors, including potentially influential medication in the investigated association 17 ; and accurate forearm ischemia-induced FMD measurement under strict quality management by standardized protocol and certified staff. 20 The method of forearm ischemia induction of FMD precludes the potential contribution of ischemia of the brachial artery itself-in contrast to upper arm ischemia-induced FMD, which is known to induce greater vasodilation. 10 The relevance of our main finding (ie, the association of low testosterone levels with impaired FMD) was corroborated by the absence of associations of testosterone levels with NMD.
In conclusion, lower serum total and free testosterone levels are associated with impaired endothelial function in this population-based sample of men, which could contribute to a possible explanation of the increased cardiovascular morbidity and mortality risk in men with lower testosterone levels. Our findings may form the basis for longitudinal studies. In addition to the existing experimental evidence of testosterone administration on vascular function, 28 confirmation of our findings by other studies could further justify testing of the effects of testosterone substitution on endothelial function, cardiovascular risk factors, cardiovascular and general health, and cardiovascular and all-cause mortality in large randomized interventional studies.
